Back to School: How biopharma can reboot drug development. Access exclusive analysis here
In a double-blind Phase III trial in 63 post-splenectomy ITP patients, 16 of 42 of patients (38%) who received
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury